IGC Pharma Statistics
Total Valuation
IGC Pharma has a market cap or net worth of $26.57 million. The enterprise value is $25.59 million.
Important Dates
The next estimated earnings date is Tuesday, February 17, 2026, before market open.
| Earnings Date | Feb 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
IGC Pharma has 95.82 million shares outstanding. The number of shares has increased by 19.49% in one year.
| Current Share Class | 95.82M |
| Shares Outstanding | 95.82M |
| Shares Change (YoY) | +19.49% |
| Shares Change (QoQ) | +8.95% |
| Owned by Insiders (%) | 7.97% |
| Owned by Institutions (%) | 20.09% |
| Float | 88.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.73 |
| Forward PS | n/a |
| PB Ratio | 3.15 |
| P/TBV Ratio | 8.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 23.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.32, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.32 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -83.34% and return on invested capital (ROIC) is -63.56%.
| Return on Equity (ROE) | -83.34% |
| Return on Assets (ROA) | -50.31% |
| Return on Invested Capital (ROIC) | -63.56% |
| Return on Capital Employed (ROCE) | -98.37% |
| Weighted Average Cost of Capital (WACC) | 6.02% |
| Revenue Per Employee | $15,800 |
| Profits Per Employee | -$92,086 |
| Employee Count | 70 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0.55 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.02% in the last 52 weeks. The beta is 0.33, so IGC Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -15.02% |
| 50-Day Moving Average | 0.31 |
| 200-Day Moving Average | 0.34 |
| Relative Strength Index (RSI) | 38.80 |
| Average Volume (20 Days) | 429,823 |
Short Selling Information
The latest short interest is 377,332, so 0.39% of the outstanding shares have been sold short.
| Short Interest | 377,332 |
| Short Previous Month | 292,751 |
| Short % of Shares Out | 0.39% |
| Short % of Float | 0.43% |
| Short Ratio (days to cover) | 0.41 |
Income Statement
In the last 12 months, IGC Pharma had revenue of $1.11 million and -$6.45 million in losses. Loss per share was -$0.08.
| Revenue | 1.11M |
| Gross Profit | 511,000 |
| Operating Income | -8.10M |
| Pretax Income | -6.45M |
| Net Income | -6.45M |
| EBITDA | -7.52M |
| EBIT | -8.10M |
| Loss Per Share | -$0.08 |
Full Income StatementBalance Sheet
The company has $1.13 million in cash and $146,000 in debt, with a net cash position of $984,000 or $0.01 per share.
| Cash & Cash Equivalents | 1.13M |
| Total Debt | 146,000 |
| Net Cash | 984,000 |
| Net Cash Per Share | $0.01 |
| Equity (Book Value) | 8.09M |
| Book Value Per Share | 0.09 |
| Working Capital | 490,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.54 million and capital expenditures -$82,000, giving a free cash flow of -$5.63 million.
| Operating Cash Flow | -5.54M |
| Capital Expenditures | -82,000 |
| Free Cash Flow | -5.63M |
| FCF Per Share | -$0.06 |
Full Cash Flow StatementMargins
| Gross Margin | 46.20% |
| Operating Margin | -731.92% |
| Pretax Margin | -582.82% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IGC Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.49% |
| Shareholder Yield | -19.49% |
| Earnings Yield | -24.26% |
| FCF Yield | -21.17% |
Analyst Forecast
The average price target for IGC Pharma is $4.13, which is 1,389.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.13 |
| Price Target Difference | 1,389.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 19, 2013. It was a reverse split with a ratio of 1:10.
| Last Split Date | Apr 19, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
IGC Pharma has an Altman Z-Score of -10.12 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.12 |
| Piotroski F-Score | 3 |
